Article Text

PDF
Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients
  1. D L Easty1,
  2. G Nemeth-Wasmer2,
  3. J-P Vounatsos3,
  4. B Girard4,
  5. N Besnainou5,
  6. P Pouliquen6,
  7. L Delval6,
  8. J-F Rouland7
  1. 1Department of Ophthalmology, Bristol Eye Hospital, Lower Maudlin Street, Bristol BS1 2LX, UK
  2. 25 place du 2 Février, 68000 Colmar, France
  3. 330 cours de l’Intendance, 33000 Bordeaux, France
  4. 441 rue de Liège, 75008 Paris, France
  5. 59 avenue de la République, 94700 Maisons Alfort, France
  6. 6Laboratoires THEA, 12 rue Louis-Blériot, ZI du Brézet, 63017 Clermont-Ferrand Cedex 2, France
  7. 7Hôpital Huriez, Aile Ouest, Service d’Ophtalmologie, Place de Verdun, 59000 Lille, France
  1. Correspondence to: Professor David L Easty Department of Ophthalmology, Bristol Eye Hospital, Lower Maudlin Street, Bristol BS1 2LX, UK; david.easty{at}bristol.ac.uk

Abstract

Aim: This comparative, open design, phase III study was to assess the non-inferiority of the non-preserved T-Gel 0.1% single dose unit (SDU) versus its preserved multidose (MD) reference.

Methods: 175 patients with bilateral POAG or OHT were randomised: 87 patients were to receive one drop daily of T-Gel 0.1% MD and 88 patients were to receive one drop daily of T-Gel 0.1% SDU, for a treatment period of 12 weeks. The primary efficacy variable was the change in intraocular pressure (IOP) in the worse eye between the baseline and the last assessment. Subjective and objective ocular signs as well as adverse events were recorded for safety. Global tolerance was assessed by the investigator and by the patient.

Results: The mean percentage reduction from baseline IOP was 24% for both treatments groups, which was consistent with previous studies. The safety results were comparable in both treatment groups. Because of gel formulation, mild short lasting episodes of blurred vision occurred for about 20% of patients. The global tolerance assessment reported that both treatments were well tolerated.

Conclusion: The overall study results demonstrated that T-Gel 0.1% SDU is not inferior to T-Gel 0.1% MD.

  • AEs, adverse events
  • BAK, benzalkonium chloride
  • BUT, break up time
  • IOP, intraocular pressure
  • LOQ, lower limit of quantification
  • MD, multidose
  • OHT, ocular hypertension
  • POAG, primary open angle glaucoma
  • SDU, single dose unit
  • VA, visual acuity
  • intraocular pressure
  • primary open angle glaucoma
  • ocular hypertension
  • timolol gel
  • AEs, adverse events
  • BAK, benzalkonium chloride
  • BUT, break up time
  • IOP, intraocular pressure
  • LOQ, lower limit of quantification
  • MD, multidose
  • OHT, ocular hypertension
  • POAG, primary open angle glaucoma
  • SDU, single dose unit
  • VA, visual acuity
  • intraocular pressure
  • primary open angle glaucoma
  • ocular hypertension
  • timolol gel

Statistics from Altmetric.com

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.